company background image
NBIX logo

Neurocrine Biosciences NasdaqGS:NBIX Stock Report

Last Price

US$123.29

Market Cap

US$12.1b

7D

-1.8%

1Y

11.1%

Updated

20 Nov, 2024

Data

Company Financials +

Neurocrine Biosciences, Inc.

NasdaqGS:NBIX Stock Report

Market Cap: US$12.1b

NBIX Stock Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. More details

NBIX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

Neurocrine Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Neurocrine Biosciences
Historical stock prices
Current Share PriceUS$123.29
52 Week HighUS$157.98
52 Week LowUS$109.77
Beta0.35
11 Month Change5.76%
3 Month Change-19.19%
1 Year Change11.09%
33 Year Change40.33%
5 Year Change4.70%
Change since IPO886.32%

Recent News & Updates

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

Recent updates

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

The Play On Neurocrine Biosciences

Oct 02

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Aug 28

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Jul 28
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Apr 27
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Apr 25

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11
Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08
We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Shareholder Returns

NBIXUS BiotechsUS Market
7D-1.8%-6.5%-1.0%
1Y11.1%14.6%30.3%

Return vs Industry: NBIX underperformed the US Biotechs industry which returned 14.6% over the past year.

Return vs Market: NBIX underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is NBIX's price volatile compared to industry and market?
NBIX volatility
NBIX Average Weekly Movement6.5%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: NBIX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NBIX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19921,700Kyle Ganowww.neurocrine.com

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.

Neurocrine Biosciences, Inc. Fundamentals Summary

How do Neurocrine Biosciences's earnings and revenue compare to its market cap?
NBIX fundamental statistics
Market capUS$12.06b
Earnings (TTM)US$385.90m
Revenue (TTM)US$2.24b

32.3x

P/E Ratio

5.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NBIX income statement (TTM)
RevenueUS$2.24b
Cost of RevenueUS$716.20m
Gross ProfitUS$1.53b
Other ExpensesUS$1.14b
EarningsUS$385.90m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.81
Gross Margin68.07%
Net Profit Margin17.21%
Debt/Equity Ratio0%

How did NBIX perform over the long term?

See historical performance and comparison